2型糖尿病并发骨质疏松患者血清Asprosin,MIP-1β水平与骨密度及骨代谢指标的相关性  

Correlation of Serum Asprosin,MIP-1βLevels with Bone Mineral Density and Bone Metabolism Indexes in Patients with Type 2 Diabetes Mellitus Combined with Osteoporosis

作　　者：张艳秋 王晓军[1] 张莹 刘丹[1] ZHANG Yanqiu;WANG Xiaojun;ZHANG Ying;LIU Dan(Department of Endocrinology,Chengde Central Hospital,Hebei Chengde 067000,China)

机构地区：[1]承德市中心医院内分泌科,河北承德067000

出　　处：《现代检验医学杂志》2024年第5期135-139,145,共6页Journal of Modern Laboratory Medicine

基　　金：河北省卫健委2021年度医学科学研究课题项目(20211478)。

摘　　要：目的探究2型糖尿病并发骨质疏松患者血清白脂素(Asprosin)、巨噬细胞炎症蛋白-1β(macrophageinflammato-ry protein-1β,MIP-1β)水平与骨密度及骨代谢指标的相关性。方法选取2022年4月~2023年4月在承德市中心医院就诊的172例2型糖尿病患者为研究对象,并根据骨密度值结果分为2型糖尿病组(n=103)和2型糖尿病并发骨质疏松组(n=69);采用ELISA法测定血清Asprosin,MIP-1β水平;Pearson法分析血清Asprosin,MIP-1β表达水平与骨密度的相关性;Logistic回归分析2型糖尿病并发骨质疏松的影响因素;受试者工作特征(ROC)曲线分析血清Asprosin,MIP-1β水平对2型糖尿病并发骨质疏松的预测价值。结果与2型糖尿病组比,2型糖尿病并发骨质疏松组患者血清β-CTX(0.48±0.08ng/ml vs 0.42±0.04ng/ml),Asprosin(2.26±0.56ng/ml vs 1.65±0.36ng/ml),MIP-1β(26.01±6.43pg/ml vs 19.46±4.27pg/ml)水平均显著升高,骨密度(0.67±0.13g/cm2 vs 0.84±0.17g/cm2),BGP(8.33±1.23ng/ml vs 9.54±1.42ng/ml),T-P1NP(30.38±3.27ng/ml vs 32.49±3.29ng/ml)水平降低,差异具有统计学意义(t=6.501,8.699,8.032,7.039,5.773,4.133,均P<0.05);Pearson法分析显示,2型糖尿病并发骨质疏松组患者血清Asprosin,MIP-1β水平均与骨密度呈负相关(r=-0.484,-0.498,均P<0.05);Logistic回归分析显示血清Asprosin,MIP-1β水平均为影响2型糖尿病并发骨质疏松发生的独立危险因素(均P<0.05);ROC曲线分析显示,血清Asprosin,MIP-1β水平预测2型糖尿病患者并发骨质疏松的AUC分别为0.768,0.704,联合预测的AUC为0.859,优于二者单独预测(Z=1.812,2.895,均P<0.05)。。结论2型糖尿病患者并发骨质疏松患者血清Asprosin,MIP-1β水平显著升高,二者水平与骨密度密切相关,血清Asprosin,MIP-1β是2型糖尿病发生骨质疏松的独立危险因素,二者联合检测对疾病发展有较高的预测价值。Objective To investigate the correlation between serum Asprosin,macrophage inflammatory protein-1β(MIP-1β)levels and bone mineral density and bone metabolism indexes in patients with type 2 diabetes mellitus(T2DM)combined with osteoporosis.Methods A tatal of 172 patients with T2DM attending Chengde City Central Hospital from April 2022 to April 2023 were selected for the study,and they were divided into T2DM group(n=103)and T2DM combined with osteoporosis group(n=69)according to the results of bone mineral density.Serum Asprosin and MIP-1βlevels were measured by ELISA.Pearson method was used to analyze the correlation between serum Asprosin,MIP-1βexpression levels and bone mineral density.Logistic regression was used to analyze the factors affecting T2DM combined with osteoporosis,and the receiver operating characteristic(ROC)curve was used to analyze the predictive value of serum Asprosin and MIP-1βlevel on T2DM combined with osteoporosis.Results Compared with the T2DM group,patients in the T2DM combined with osteoporosis group had higher levels of serumβ-CTX(0.48±0.08ng/ml vs 0.42±0.04ng/ml),Asprosin(2.26±0.56ng/ml vs 1.65±0.36ng/ml)and MIP-1β(26.01±6.43pg/ml vs 19.46±4.27pg/ml),while BMD(0.67±0.13g/cm2 vs 0.84±0.17g/cm2),BGP(8.33±1.23ng/ml vs 9.54±1.42ng/ml)and T-P1NP(30.38±3.27ng/ml vs 32.49±3.29ng/ml)levels were decreased,with statistically significant differences(t=6.501,8.699,8.032,7.039,5.773,4.133,all P<0.05).Pearson method analysis showed that serum Asprosin and MIP-1βlevels were negatively correlated with bone mineral density of patients in the T2DM combined with osteoporosis group(r=-0.484,-0.498,all P<0.05).Logistic regression analysis showed that serum Asprosin and MIP-1βlevels were independent risk factors influencing the occurrence of T2DM combined with osteoporosis(all P<0.05).ROC curve analysis showed that the AUCs of serum Asprosin and MIP-1βlevels predicted T2DM combined osteoporosis were 0.768 and 0.704,respectively,and the AUC of both combined prediction was 0.859,which

关 键 词：白脂素 巨噬细胞炎症蛋白-1β 2型糖尿病 骨质疏松 

分 类 号：R587.2[医药卫生—内分泌] R446.11[医药卫生—内科学]